Nuvo Research Inc.
1405 Denison Street
Markham
Ontario
L3R 5V2
Canada
Tel: 905-415-1446 or 1-888-398-3463
Fax: 905-415-1440
Website: http://www.nuvoresearch.com/
Email: info@nuvoresearch.com
163 articles about Nuvo Research Inc.
-
Nuvo Research Completes Reorganization Into Two Publicly Traded Companies
3/1/2016
-
Nuvo Research Obtains Final Court Order Approving Reorganization Into Two Publicly-Traded Companies
2/25/2016
-
Nuvo Research Announces 2015 Fourth Quarter & Year-End Results
2/18/2016
-
Nuvo Research And Horizon Pharma Extend Term Of Manufacturing Agreement
2/8/2016
-
Nuvo Research Provides Estimated Revenue For The 2015 Fourth Quarter And Year End
1/21/2016
-
Nuvo Research Reacquires Pliaglis North American Development And Marketing Rights
12/22/2015
-
Nuvo Research to Discontinue all WF10 Development
12/21/2015
-
Nuvo Research Announces Special Shareholder Meeting To Vote On Reorganization Of Nuvo Into Two Publicly Traded Companies
12/15/2015
-
Nuvo Research Provides Update on Pennsaid® 2% Phase 3 Clinical Trial
12/3/2015
-
Nuvo Research Announces Acceleration Of Expiry Date Of Outstanding Warrants
11/30/2015
-
Nuvo Research Announces TSX Conditional Approval To List Crescita Therapeutics Inc.
11/23/2015
-
Nuvo Research Announces 2015 Third Quarter Results
11/11/2015
-
Nuvo Research Announces Successful Pennsaid2% Phase 3 Trial For Russia
11/5/2015
-
Nuvo Research Announces Appointment To Its Board Of Directors
11/3/2015
-
Nuvo Research Explores Splitting Company into Separate Entities
9/16/2015
-
Nuvo Research Inc. Announces U.S. Patent For Topical Foamed Formulations That Include DMSO
8/20/2015
-
Nuvo Research Inc. Announces Grant Of United States Patent For Topical Onychomycosis Formulation
8/11/2015
-
Nuvo Research Inc. Announces 2015 Second Quarter Results
8/6/2015
-
Nuvo Research Inc. Provides Update On International Licensing Of Pennsaid 2%
6/24/2015
-
Nuvo Research Inc. Receives Health Canada Approval To Conduct New WF1 Phase 2 Trial
6/8/2015